Researchmoz added Most up-to-date research on "Gastric and Esophageal Cancer Drug Development: Key Companies - Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca" to its huge collection of research reports.
This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a total of 107 products in development for this indication, by 79 companies and 11 academic institutions.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394150
Key targets in development across both indications include human epidermal growth factors 1 and 2, and programmed cell death protein 1. In addition, the hepatocyte and vascular endothelial growth factors are being developed across many pipeline programs in gastric cancer.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Browse TOC @ https://www.researchmoz.us/gastric-and-esophageal-cancer-drug-development-pipeline-review-2017-report.html/toc
Table of Contents
1 Table of Contents
2 Introduction 10
2.1 Gastric and Esophageal Cancer Report Coverage 10
2.2 Esophageal Cancer Overview 10
2.3 Gastric Cancer Overview 10
3 Therapeutics Development 11
3.1 Esophageal Cancer 11
3.2 Gastric Cancer 21
4 Therapeutics Assessment 45
4.1 Esophageal Cancer 45
4.2 Gastric Cancer 56
5 Companies Involved in Therapeutics Development 78
5.1 Esophageal Cancer 78
5.2 Gastric Cancer 109
This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a total of 107 products in development for this indication, by 79 companies and 11 academic institutions.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1394150
Key targets in development across both indications include human epidermal growth factors 1 and 2, and programmed cell death protein 1. In addition, the hepatocyte and vascular endothelial growth factors are being developed across many pipeline programs in gastric cancer.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Browse TOC @ https://www.researchmoz.us/gastric-and-esophageal-cancer-drug-development-pipeline-review-2017-report.html/toc
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 9
1.1 List of Tables 5
1.2 List of Figures 9
2 Introduction 10
2.1 Gastric and Esophageal Cancer Report Coverage 10
2.2 Esophageal Cancer Overview 10
2.3 Gastric Cancer Overview 10
3 Therapeutics Development 11
3.1 Esophageal Cancer 11
3.2 Gastric Cancer 21
4 Therapeutics Assessment 45
4.1 Esophageal Cancer 45
4.2 Gastric Cancer 56
5 Companies Involved in Therapeutics Development 78
5.1 Esophageal Cancer 78
5.2 Gastric Cancer 109
No comments:
Post a Comment